Staying on 2.5mg Mounjaro: when it makes sense and when to think again

You've taken your fourth 2.5mg pen and you're wondering whether to stay

That moment (the fourth pen sitting in the fridge door, the titration reminder arriving) is where most people start asking this question. You might feel fine on 2.5mg but notice the scales haven't shifted much. Or the first few weeks were rough and you've only just settled. Both are common situations, and both are genuinely different clinical scenarios despite sounding similar on the surface.

Tirzepatide's 2.5mg dose exists for one specific reason: to give your digestive system four weeks to adapt before the dose climbs. The NHS patient information for tirzepatide describes this dose explicitly as the starting level, with the schedule moving upward every four weeks under prescriber guidance. That framing matters. It tells you that the licence, and the clinical intent behind it, treats 2.5mg as a runway rather than a destination.

That said, the licensed schedule is a framework, not a rigid timetable. Prescribers regularly hold patients at a dose for longer when there is a clinical reason, a period of illness, a temporary spike in side effects, or a need to stabilise before climbing. What is not supported by the evidence is staying at 2.5mg indefinitely with no plan to review, because the weight-management benefit of the medicine is substantially linked to reaching and maintaining a higher therapeutic dose. If you want to read more about how long staying at 2.5mg is typically appropriate, that page goes into the timing in more detail.

What actually happens at 2.5mg, and why the clinical trials don't separate it out

SURMOUNT-1, the pivotal trial involving thousands of adults with obesity, demonstrated average weight reductions of around 20–21% at the 15mg maintenance dose over 72 weeks. Those results are cited frequently, and rightly. What they don't show is a 2.5mg-specific figure, because no participant stayed at 2.5mg for the full trial, everyone titrated. NICE's appraisal of tirzepatide (TA1026) similarly bases its recommendation on the full titration programme, not on the starter dose in isolation.

That absence of data is itself informative. There is no published evidence base for long-term 2.5mg-only treatment, because that was never the design. The mechanism helps explain why: tirzepatide activates both GIP and GLP-1 receptors to reduce appetite and slow gastric emptying. Those effects are dose-dependent, meaning higher doses generally produce stronger appetite regulation. Staying at the lowest dose keeps those effects mild, which is why many people at 2.5mg report only modest hunger changes compared with what they experience at 5mg or above.

This is also why questions about how much tirzepatide is needed for meaningful weight loss don't have a single answer, it depends on your response, your tolerability, and how your prescriber interprets your progress across the whole picture, not just one number on a scale.

When staying at 2.5mg is reasonable and when it is a concern

There are legitimate short-term reasons a prescriber might recommend staying at 2.5mg for longer than four weeks. Persistent nausea, vomiting, or significant GI upset that hasn't settled is the most common. In those cases, extending the starter dose gives the body more time to adjust before the next step. If you've had a gap in treatment or restarted after stopping, your prescriber may also drop you back to 2.5mg temporarily as a safety measure.

What is a concern is staying at 2.5mg without clinical oversight, either because you've decided to pause your own titration without telling your prescriber, or because you have no ongoing prescriber relationship reviewing your treatment. Mounjaro is a prescription-only medicine, and every dose decision, including the decision to stay put, should be made with your clinical team. Some people do find that staying on 2.5mg of Mounjaro is the right choice for their circumstances, and that page sets out what the evidence and prescriber guidance say about making that call. If you've been wondering about the overlap between this dose and the next, whether staying at 5mg long-term is more appropriate for your situation is a related question worth putting to your prescriber too.

Cost is sometimes a factor in people's thinking here, and it's worth naming honestly. Staying at 2.5mg doesn't necessarily lower the overall cost of treatment in a meaningful way when weighed against slower progress. If understanding what drives Mounjaro pricing in the UK is part of your thinking, that page covers the market context without sugarcoating it. What it won't change is the clinical picture: the medicine works best at the dose your prescriber determines is right for you, and that decision is worth having properly.

How a prescriber at a regulated service reviews this with you

At a GPhC-registered online pharmacy like nume, no repeat order goes out without a clinical review. A real prescriber reads your progress (not a form processed by software) before any pen is dispensed. If you're staying at 2.5mg and your prescriber hasn't discussed why, that's the conversation to have. Patients who are considering moving to the next stage may also find it useful to read about how long it's appropriate to stay on 5mg Mounjaro before titrating further, so they can go into that conversation with their prescriber informed. If you're new to Mounjaro and weighing up where to start, our clinical team, including our lead prescriber, reviews every consultation the same day it comes in.

The question of whether staying at 2.5mg is right for you isn't one a content page can answer, but a prescriber can, and should, at every repeat. If you'd like that review, starting with a free consultation is the straightforward next step.